RxDoctor Payments DataLook up a doctor →

Joseph Miller, MD

Cardiovascular Disease · Atlanta, GANPI 1083624936

Payments from drug & device makers

$770,640in general payments, 2019–2025

Across 755 payments — averaging $1020.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$504K
  • Novartis$210K
  • Esperion Therapeutics, Inc.$54K
  • Medtronic$495
  • Biotronik Inc.$260
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$140
  • plus $742 from 11 others
$10,843in research payments, 2019–2025

Across 1 payment — averaging $10,843 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis$11K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$770,640 in reported general payments places this provider in the 95th percentile of 640 cardiovascular disease providers in Georgia.

See all cardiovascular disease providers in Georgia

Medicare billing

Part B allowed, 2024
$74,305
Medicare patients
497
Services billed
766

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other cardiovascular disease in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →